Xeris Biopharma Holdings, Inc.
XERSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for XERS. That does not mean none is planned.
Get an email about XERS's next catalysts
Track Xeris Biopharma Holdings (XERS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
How XERS's past catalysts played out
Market Overview
Stock performance and key metrics
Glucagon
Diabetes Mellitus, Type 1
Novo Glucagon
Insulin Hypoglycemia
G-Pen (glucagon injection)
Hypoglycemia
G-Pen
Insulin Hypoglycemia
Lilly Glucagon (glucagon injection)
Hypoglycemia
Lilly Glucagon
Insulin Hypoglycemia
G-Pen Mini™ (glucagon injection)
Hypoglycemia
G-Pen(TM)
Hypoglycemia
Glugaon RTU Injection Without Insulin Pump Reduction
Hypoglycemia
Regular Insulin + Pramlintide
Diabetes Mellitus, Type 1
Regular Insulin
Diabetes Mellitus, Type 1
PRAM9
Diabetes Mellitus, Type 1
Lilly Glucagon(TM)
Hypoglycemia
Novo Nordisk GlucaGen®
Hypoglycemia
levothyroxine sodium
Hypothyroidism
G-Pump™ (glucagon infusion)
Hypoglycemia
Glucagon RTU
Hyperinsulinemic Hypoglycemia
Glucagon RTU Injection With Insulin Pump Reduction
Hypoglycemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Glucagon | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Novo Glucagon | Phase 3 | Insulin Hypoglycemia | - | - |
G-Pen (glucagon injection) | Phase 3 | Hypoglycemia | - | - |
G-Pen | Phase 3 | Insulin Hypoglycemia | - | - |
Lilly Glucagon (glucagon injection) | Phase 3 | Hypoglycemia | - | - |
Lilly Glucagon | Phase 3 | Insulin Hypoglycemia | - | - |
G-Pen Mini™ (glucagon injection) | Phase 2 | Hypoglycemia | - | - |
G-Pen(TM) | Phase 2 | Hypoglycemia | - | - |
Glugaon RTU Injection Without Insulin Pump Reduction | Phase 2 | Hypoglycemia | - | - |
Regular Insulin + Pramlintide | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Regular Insulin | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
PRAM9 | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Lilly Glucagon(TM) | Phase 2 | Hypoglycemia | - | - |
Novo Nordisk GlucaGen® | Phase 2 | Hypoglycemia | - | - |
levothyroxine sodium | Phase 2 | Hypothyroidism | - | - |
G-Pump™ (glucagon infusion) | Phase 2 | Hypoglycemia | - | - |
Glucagon RTU | Phase 2 | Hyperinsulinemic Hypoglycemia | - | - |
Glucagon RTU Injection With Insulin Pump Reduction | Phase 2 | Hypoglycemia | - | - |
Frequently asked questions
What is in Xeris Biopharma Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in Xeris Biopharma Holdings, Inc.'s (XERS) pipeline across Phase 3, Phase 2. Its lead program is G-Pen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Xeris Biopharma Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Xeris Biopharma Holdings, Inc. (XERS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track XERS biotech catalysts?→
Add XERS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Xeris Biopharma Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.